Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Dyne Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., August 3, 2023 – Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2023 and business highlights. “This is an exciting time for the entire Dyne team as we continue to enroll and dose patients in our ACHIEVE and DELIVER trials and are on track to report our first clinical data from both during the second half of this year, including evalua..."
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/15/2023 144 Form 144 - Report of proposed sale of securities:
06/12/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., May 11, 2023 – Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2023 and business highlights. “We are making excellent progress in both our ACHIEVE and DELIVER trials and are on track to report initial data from both in the second half of 2023, including evaluating the key disease-driving biomarkers of splicing in DM1 and dystrophin in DM..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights - Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD -"
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/09/2023 SC 13G/A MPM BIOVENTURES 2018, L.P. reports a 9.5% stake in Dyne Therapeutics, Inc.
02/09/2023 SC 13G BlackRock Inc. reports a 4.9% stake in DYNE THERAPEUTICS INC
02/08/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/14/2022 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DYNE THERAPEUTICS, INC.
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/12/2022 8-K Other Events  Interactive Data
08/04/2022 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 -"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/05/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
Docs: "Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 -"
05/02/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/22/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/22/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2022 8-K Quarterly results
03/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/10/2022 10-K Annual Report for the period ended December 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy